Loading...
•
Jun 30, 2024
Solventum Q2 2024 Earnings Report
Solventum's Q2 2024 financial results were reported, with sales increasing and full-year guidance raised.
Key Takeaways
Solventum reported its Q2 2024 financial results, highlighting a slight increase in reported sales and organic sales growth. The company's GAAP EPS was $0.51, while adjusted EPS reached $1.56. Solventum generated $355 million in cash from operations and $297 million in free cash flow. The company also raised its full-year 2024 organic sales growth and adjusted EPS guidance.
Reported sales increased by 0.2% to $2.081 billion, with organic sales up by 1.3%.
GAAP Earnings Per Share (EPS) was $0.51, and adjusted EPS was $1.56.
Cash from operations amounted to $355 million, with a free cash flow of $297 million.
Full-year 2024 organic sales growth and adjusted EPS guidance were raised.
Solventum
Solventum
Solventum Revenue by Segment
Revenue by Segment
MedSurg Revenue
CapyFin.comDental Solutions Revenue
CapyFin.comHealth Info Systems Revenue
CapyFin.comPurification & Filtration Revenue
CapyFin.comAdvanced Wound Care Revenue
CapyFin.comInfection Prevention & Surgical Revenue
CapyFin.com Forward Guidance
Solventum is raising its full-year 2024 guidance.
Positive Outlook
- Organic sales growth of 0% to +1.0% (previously -2% to 0%)
- Adjusted EPS of $6.30 to $6.50 (previously $6.10 to $6.40)
- Free cash flow of $700M to $800M (no change to prior guidance)
Revenue & Expenses
Visualization of income flow from segment revenue to net income